Table 4.
PhaseI-II studies of regimens as first and second lines chemotherapy in advanced pancreatic cancer
| Regimen | Number of patients | TCR/ORR (%/%) | TTP or PFS (mo) | OS (mo) |
| Phase I-II studies1 | ||||
| Irinotecan/gemcitabine/5-FU[27] | 30 | 43/7 | 3.4 | 8.3 |
| G-FLIP (Irinotecan/gemcitabine/5-FU/cisplatin)[28] | 31 | 68/26 | 6.1 | 8.1 |
| FOLFIRI-3 (Irinotecan/5-FU)[20] | 40 | 65/38 | 5.6 | 12.1 |
| Irinotecan/S1[29] | 16 | 75/44 | 4.9 | 11.3 |
| Phase II studies2 | ||||
| Irinotecan/raltitrexed[32] | 19 | 53/16 | 4.0 | 6.5 |
| IROX (Irinotecan/oxaliplatin)[33] | 30 | 33/10 | 4.1 | 5.9 |
| IROX (Irinotecan/oxaliplatin)[34] | 14 | 50/21 | 1.4 | 4.1 |
| G-FLIP (Irinotecan/gemcitabine/5-FU/cisplatin)[35] | 34 | 44/24 | 3.9 | 10.3 |
| Irinotecan/docetaxel[36] | 14 | 21/0 | 1.2 | 4.4 |
| MDI (Irinotecan/mitomycin/docetaxel)[37] | 15 | 20/0 | 1.7 | 6.1 |
1
Phases I-II studies of irinotecan and 5-fluorouracil (5-FU)-based regimens as first line chemotherapy;
2
Phase II studies of irinotecan-based regimens as second line chemotherapy. TCR: Tumor control rate; ORR: Overall response rate; TTP: Time to progression; PFS: Progression free survival; OS: Overall survival.